key: cord-0923032-ptfhj0p5
authors: Altamimi, Asmaa M.; Obeid, Dalia A.; Alaifan, Taghreed A.; Taha, Moroje T.; Alhothali, Marwa T.; Alzahrani, Fahad A.; Albarrag, Ahmad M.
title: Assessment of 12 qualitative RT‐PCR commercial kits for the detection of SARS‐CoV‐2
date: 2021-03-17
journal: J Med Virol
DOI: 10.1002/jmv.26900
sha: d080a61863896ef15d3737fb607165c1d9dbe72f
doc_id: 923032
cord_uid: ptfhj0p5

The emergence of the novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in the late months of 2019 had the officials to declare a public health emergency leading to a global response. Public measurements rely on an accurate diagnosis of individuals infected with the virus by using real‐time reverse transcriptase‐polymerase chain reaction (RT‐PCR). The aim of our study is to relate the fundamental clinical and analytical performance of SARS‐CoV‐2 (RT‐PCR) commercial kits. A total of 94 clinical samples were selected. Generally, 400 µl of each respiratory specimen was subjected to extraction using ExiPrep 96 Viral RNA Kit. All kits master mix preparation, cycling protocol, thermocycler, and results interpretation were carried out according to the manufacturer's instructions of use and recommendations. The performance of the kits was comparable except for the LYRA kit as it was less sensitive (F = 67, p < .001). Overall, four kits scored a sensitivity of 100% including: BGI, IQ Real, Sansure, and RADI. For specificity, all the tested kits scored above 95%. The performance of these commercial kits by gene target showed no significant change in CT values which indicates that kits disparities are mainly linked to the oligonucleotide of the gene target. We believe that most of the commercially available RT‐PCR kits included in this study can be used for routine diagnosis of patients with SARS‐CoV‐2. We recommend including kits with multiple targets in order to monitor the virus changes over time.

The emergence of the novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the late months of 2019 had the officials to declare a public health emergency leading to a global response. 1 The new virus (SARS-CoV-2) has been identified as a new strain of Betacoronvirus from group 2B with approximately 70% genetic similarity to the severe acute respiratory syndrome coronavirus (SARS-CoV). 2 including the RNA-dependent RNA polymerase (RdRP) protein which is important for virus replication and transcription. 3 In response to the burden of the current pandemic, strict measurements were globally implemented to stop further transmission of the virus. These measurements rely on an accurate diagnosis of individuals infected with the virus by using real-time reverse-transcriptase polymerase chain reaction (RT-PCR). 4 The most common targets for detecting SARS-CoV-2 by (RT-PCR) assays in diagnostic laboratories are the ORF1ab gene, the RdRP gene, the E gene, the N gene, and the S gene. 5 The SARS-CoV-2 pandemic caused a huge burden on the societal, financial, and healthcare systems in the sphere, and various measures were implemented to control its spread. Most of the control measures mainly depend on the precise testing of the individuals infected by the virus. The real-time RT-PCR method of detection is the most common and reliable test in detecting viral genome, therefore the world health organization (WHO) has recommended the use of this method as the gold standard during the current time. 6 Many SARS-CoV-2 RT-PCR diagnostic kits have become commercially available in the market; however, the evaluation of most of the kits' performance is not available to the public sector. 7 In the Saudi Center for Disease Prevention and Control (SCDC) 

Generally, 400 μl of each respiratory specimen was extracted using Table 1 ). When the result was inconclusive or invalid, as per the manufacturer's results interpretation, retesting was performed, and no PCR inhibition was noted. agreed on the result. The sensitivity and specificity were calculated according to the Trevethan 2017 reference study. 8 The golden standard result was used conducting kappa agreement tests between the kits. All p values reported are two-sided and were considered to be statistically significant at alpha less than .05.

The 94 samples were all processed, and the results were interpreted as recommended by each of the kits' manufacturer recommendations. Kits with single targets were reported positive if their CT were below the cutoff value. All samples were tested by all kits except for the RADI, we only had enough for 55 samples, therefore we selected the enrolled samples randomly. The summary of the detection results is shown in Figure 1 . Multiple 

The summary of the sensitivity and specificity tests for the 12 commercial kits is shown in Table 3 10 In our study, we did not evaluate the limit of detection (LOD) which can play a big role, as with several of the commercial kits approved for the pandemic situation many were approved without evaluation with appropriate numbers F I G U R E 2 Box plot of the positive samples' cycling threshold (CT) values across the 12 diagnostic kits (gene targets). The whisker above the box plot represents the upper limit of the 95% confidence interval, while the bottom line represents the lower limit of the 95% confidence interval, the red line represents the cutoff value reported in the kit user guide. The lowest CT values were mostly reported with KAIRA (E gene target), Sansure (N gene target), and TaqPath (N gene target). The highest positive CT values were mostly reported with PowerCheck (RdRP gene target), LightMix (E gene target), and Genesig (RdRP gene target). ANOVA test was significant by the CT value reported by the multiple kits. ANOVA, analysis of variance F I G U R E 3 Box plot of the positive samples cycling threshold (CT) values across the testing kits targets. The whisker above the box plot represents the 95% upper confidence interval, while the bottom line represents the lower 95% confidence interval. The lowest CT value was reported with kits targeting the N gene. The highest CT values were mostly reported with kits targeting the RdRP gene of samples. 11 Another important variation source in many PCR kits results that we did not manage to evaluate is variation in instrument and technicians, in a multiple center euro surveillance study, the same commercial kits showed variation in results between different centers, many of these centers had different instruments and technicians. 12 Overall, the variation in CT values can rise from multiple areas such as extraction methods, the gene target, the oligo design, and technical aspects linked to reproducibility. One of the biggest challenges in the diagnosis of SARS-CoV-2 in clinical settings is the high rate of false-negative cases. As known with RNA viruses the mutation rate is high compared with other pathogens. Moreover, the nucleotide mutation rate reported for SARS-CoV-2 was 8E-04 substitution per site per year. 13, 14 Many studies have already shown the high evolution rate of SAR-CoV-2 in many cases and linked its evolution with its origin. 5 Detection methods using RT-PCR are based on a fixed target, however, as the pandemic proceeds the virus is changing and many cases are missed.

In one study, evaluating multiple RT-PCR targets has shown a high loss of sensitivity, with a total of 11,627 cases missed due to variations in genetic code. 15 In one of the biggest studies worldwide tracking the mutations of SARS-COV-2, one mutation D614 was decreasing and another mutation G614 mutation was growing, the new mutation has lower CT values which indicate a change in virus virulence. 16 In a genomic surveillance study, a rise in mutation located in the ORF gene was linked to the Middle East SARS-CoV-2

cases. 17 Overall, these studies indicate a high number of genetic mutations in SARS-CoV-2 globally.

This rise will cause many positive cases to be missed in the RT-PCR, which will cause a challenge with using these fixed commercial RT-PCR kits. In one case for a systematic SARS-CoV-2 case, the patient was negative in many RT-PCR tests, however, he was only positive by the antibody test, moreover, the case was later investigated with sequencing and the virus infecting the patient had two major mutations one located at the NP genes and another located at the ORF gene. 18 The escalation of these different mutations in SARS-CoV-2 at multiple geographical locations indicates the need for genetic screening periodically in each country to count for these changes as they may significantly play a role in choosing the commercial diagnostic kit used at the testing centers. Furthermore, the importance of revealing the sequence and design of the oligonucleotides in commercially available kits' description is essential at this time as the virus keeps spreading and evolving.

We are aware that our study may have several limitations. The first one is that we were not able to study the cross-reactivity of these commercial kits with other viruses which can significantly alter the results of the detection. Even though our conducted study implemented a comparative evaluation it is still not a comprehensive study as we could not include all RT-PCR diagnostic kits available at the market and the performance of some kits may vary depending on the extraction method. By changing the extraction method, some results may vary. Another area of limitation in our study is our sample size which is limited to the number of tests per kit. In our future work, we hope to evaluate genetic changes in the virus and its effect on detecting the virus by the available commercial kits.

In conclusion, we believe that most of the commercially available RT-PCR kits included in this study can be used for routine diagnosis of SARS-CoV-2 patients. Most of the kits succeeded in detecting the virus, however, few distinctions were found with specific kits and targets. Kits with multiple targets have been shown to be more sensitive and specific as they counted for target variations. Moreover, we recommend that regardless of the laboratory choice of diagnostic commercial kit for the clinical detection of patients with COVID-19, the need for a good plan for validation and collaboration with exterior laboratories is essential to monitor the changes in the virus, procedures, technicians, and the different kits performances. 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A genomic perspective on the origin and emergence of SARS-CoV-2

From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses

US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2

Diagnosing the novel SARS-CoV-2 by quantitative RT-PCR: variations and opportunities

Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2. 0) working group of 2019 novel coronavirus, Peking union medical college hospital

Preparedness of European diagnostic microbiology labs for detection of SARS-CoV-2

Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice

Comparison of seven commercial RT-PCR diagnostic kits for COVID-19

Comparison of commercial realtime reverse transcription PCR assays for the detection of SARS-CoV-2

Limits of detection of 6 approved RT-PCR kits for the novel SARS-coronavirus-2 (SARS-CoV-2)

Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2

Quasispecies theory,and the behavior of RNA viruses

Nextstrain: real-time tracking of pathogen evolution

Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East

A Confirmed case of SARS-CoV-2 pneumonia with routine RT-PCR negative and virus variation in Guangzhou, China

Assessment of 12 qualitative RT-PCR commercial kits for the detection of SARS-CoV-2

We are grateful to the support of The Saudi Center for Disease Prevention and Control Administration, and COVID-19 Team. This study was funded by Saudi CDC. The RT-PCR kits included in this study were provided free of charge.

All authors contributed to the manuscript equally. AT conducted and 

The peer review history for this article is available at https://publons. com/publon/10.1002/jmv.26900.

Data available on request from the authors.

https://orcid.org/0000-0003-0381-757X